Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inozyme Pharma, Inc. (INZY) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency - Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient reported outcomes and functional outcomes - - Improvement in the Global Impression of Change observed in all three dose cohorts in ABCC6 Deficiency trial - - INZ-701 was generally well tolerated and exhibited a favorable safety and immunogenicity profile in both trials - - Company to host conference call and webcast today at 8:00 a.m. ET -"
08/08/2023 8-K Quarterly results
Docs: "Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights – Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 – – Plasma pyrophosphate to serve as primary endpoint in the U.S. and co-primary endpoint in the EU for ENERGY-3 pediatric pivotal trial for ENPP1 Deficiency; initiation expected in October 2023 – – Cash, cash equivalents, and short-term investments as of June 30, 2023, together with proceeds from July 2023 offering, expected to fund cash flow requirements into the fourth quarter of 2025 –"
07/28/2023 8-K Quarterly results
07/26/2023 8-K Quarterly results
05/09/2023 8-K Quarterly results
Docs: "Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights - Upcoming clinical and regulatory milestones remain on track with previous guidance – - Current cash, cash equivalents and short-term investments anticipated to fund cash flow requirements into the fourth quarter of 2024 - BOSTON, May 9, 2023 – Inozyme Pharma, Inc. , a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the first quarter ended March 31, 2023, and provided business highlights. “We are continuing to advance INZ-701 and look forward to initiating a pivotal trial for pediatric patients with ENPP1 Deficiency in the third quarter of this y..."
03/22/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
12/08/2022 8-K Quarterly results
12/08/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
07/26/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
07/19/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/19/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and among Inozyme Pharma, Inc. and Jefferies LLC and Cowen and Company, LLC, as representatives of the underwriters named therein",
"Form of Pre-Funded Warrant",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market"
04/12/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency - First patient dosed in Phase 1/2 clinical trial in ABCC6 Deficiency – - Preliminary biomarker and safety data from Phase 1/2 clinical trial in ABCC6 Deficiency expected in the second quarter of 2022 – - Second cohort in Phase 1/2 clinical trial in ENPP1 Deficiency fully enrolled; topline data expected in the second half of 2022 - BOSTON, April 12, 2022 – Inozyme Pharma, Inc. , a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of INZ-701 in adult patients with ABCC6 Deficiency and the second cohort in the ongoing Phase 1/2 ..."
04/04/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency - Rapid, significant, and sustained increase in plasma pyrophosphate levels observed in all three patients in lowest dose cohort – - PPi increased in all three patients to levels comparable to those observed in a study of healthy subjects - - INZ-701 was generally well-tolerated and exhibited a favorable initial safety profile – - Second cohort underway at next dose level – BOSTON, April 4, 2022 – Inozyme Pharma, Inc. , a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced positive preliminary biomarker, safety, and pharmacokinetic data from the first three patients treated..."
03/15/2022 8-K Quarterly results
03/08/2022 8-K Quarterly results
11/15/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Excerpt from Company Presentation, dated November 2021"
08/11/2021 8-K Quarterly results
Docs: "Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights - Received Orphan Drug Designation from the European Medicines Agency for INZ-701 for the treatment of ABCC6 Deficiency –"
06/24/2021 8-K Submission of Matters to a Vote of Security Holders
05/12/2021 8-K Quarterly results
05/07/2021 8-K Quarterly results
04/21/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights"
09/03/2020 8-K Quarterly results
Docs: "Inozyme Pharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights"
07/28/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy